VivoSeq
Infectious Disease

Abdominal Abscess

2

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Abdominal Abscess is an early-stage landscape with 2 programs across 1 company. The most active players are Prism Pharmaceuticals. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Tissue Plasminogen Activator

Neuroscience Trials Australia

Approved1

Tigecycline

Prism Pharmaceuticals

Analysis

Trial Status

4

clinical trials

Not yet recruiting2 · 50%
Completed1 · 25%
Terminated1 · 25%

Clinical Trials

Trial Activity

Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
Completed·HHannover Medical School·Phase 3·NCT00629135·180 enrolled
Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study
Not yet recruiting·TThe University of Texas Health Science Center, Houston·Phase 4·NCT04200729·1,750 enrolled
Safety and Effectiveness of tPA in Intra-abdominal Abscesses
Terminated·UUniversity Health Network, Toronto·Phase 2/3·NCT00417768·35 enrolled
Abdominal aBscess Catheter Sclerotherapy (ABCS)
Not yet recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT06906029·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)